Loading…
bioAffinity Technologies, Inc. is projected to decline to $1.38 by 2027, a -17% move from its current price of $1.65. BIAF is currently trading below its 50-day average (a bearish sign). Technical indicators currently lean strong sell.
A data-driven summary — not financial advice. See the full breakdown below.
Live market data via Yahoo Finance · updated 5/28/2026
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| May 29 | $1.55 | $1.65 | $1.75 | -0.08% |
| May 30 | $1.51 | $1.65 | $1.79 | -0.15% |
| May 31 | $1.48 | $1.65 | $1.83 | -0.23% |
| Jun 1 | $1.46 | $1.64 | $1.85 | -0.31% |
| Jun 2 | $1.44 | $1.64 | $1.88 | -0.38% |
| Jun 3 | $1.42 | $1.64 | $1.90 | -0.46% |
| Jun 4 | $1.40 | $1.64 | $1.92 | -0.54% |
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| Week 1 | $1.40 | $1.64 | $1.92 | -0.54% |
| Week 2 | $1.31 | $1.63 | $2.04 | -1.07% |
| Week 3 | $1.24 | $1.62 | $2.13 | -1.60% |
| Week 4 | $1.18 | $1.61 | $2.21 | -2.12% |
| Week 5 | $1.13 | $1.61 | $2.29 | -2.65% |
| Week 6 | $1.09 | $1.60 | $2.35 | -3.17% |
| Week 7 | $1.05 | $1.59 | $2.41 | -3.69% |
Short-term targets derived from the forecast trend and recent volatility. Highly uncertain — not financial advice.
bioAffinity Technologies, Inc. engages in developing non-invasive diagnostic laboratory tests to detect early-stage lung cancer and other diseases of the lung using flow cytometry and automated analysis in the United States.
The company operates through two segments: Diagnostic Research and Development; and Laboratory Services. It offers CyPath lung, which uses flow cytometry technology to detect and analyze cell populations in a person's sputum, or phlegm, to find characteristics indicative of lung cancer, including cancer and/or cancer-related cells that have shed from a lung tumor. It has a collaboration with Brooke Army Medical Center to evaluate its proprietary tests under development to identify inflammatory biomarkers for asthma and chronic obstructive pulmonary disease.
bioAffinity Technologies, Inc. was incorporated in 2014 and is based in San Antonio, Texas.
bioAffinity Technologies, Inc. is a Healthcare company trading under the symbol BIAF. The stock currently trades at $1.56 per share and has a market cap of $7.07M, with a rank of 5254.
The technical picture shows bearish momentum, with RSI14 at 30 and the price trading below key moving averages (SMA50 at $2.75 and SMA200 at $2.91). A support level is noted at $1.56 and a resistance at $3.18. Over the last 30 days, the price has ranged from $1.04 to $2.35.
The forecast implies a mixed price outlook in the near term, with a 2026 average around $1.56 and longer-horizon averages rising to $3.31 by 2050, suggesting potential upside over time despite near-term volatility.
A major floor 59.0% below — a decisive break under it would weaken the trend.
The nearest floor, 5.5% below — buyers have tended to step in here.
The nearest ceiling, 77.6% above — a clean break opens room to run.
A major ceiling 187.3% above — clearing it would confirm fresh momentum.
Key BIAF support and resistance from recent price action — levels where the trend has historically paused or reversed. Percentages are the distance from the current price.
A snapshot of BIAF market posture derived from its technical indicators and recent volatility. Higher trend and alignment lean bullish; higher risk means larger swings.
Technical Analysis
Indicators computed on daily closing prices.
| Period | SMA | Action | EMA | Action |
|---|---|---|---|---|
| MA 5 | $1.63 | Buy | $1.65 | Sell |
| MA 10 | $1.73 | Sell | $1.74 | Sell |
| MA 20 | $1.93 | Sell | $1.94 | Sell |
| MA 50 | $2.73 | Sell | $2.19 | Sell |
| MA 100 | $1.96 | Sell | $2.39 | Sell |
| MA 200 | $2.84 | Sell | $4.79 | Sell |
| Name | Value | Action |
|---|---|---|
| RSI (14) | 36.40 | Neutral |
| Stoch RSI (14) | 41.32 | Neutral |
| CCI (20) | -87.99 | Neutral |
| Williams %R (14) | -83.93 | Info |
| MACD (12,26,9) | -0.00 | Sell |
| ROC (12) | -18.72 | Sell |
| Bollinger %B (20,2) | 0.23 | Neutral |
| Stochastic %K (14) | 16.07 | Buy |
| TRIX (15) | -1.66 | Sell |
| Awesome (5,34) | -0.64 | Sell |
| Ultimate (7,14,28) | 27.92 | Buy |
| Momentum (10) | -0.23 | Sell |
| Aroon Osc (25) | -72.00 | Sell |
| Hull MA (9) | 1.57 | Buy |
| ADX (14) | 23.30 | Sell |
| ATR (14) | 0.11 | Info |
The near-term technical picture is bearish, with RSI14 at 30 indicating weakened momentum. The 30-day range spans from $1.04 to $2.35, framing the trading band for the coming month.
Price action remains anchored at a support of $1.56 while facing resistance at $3.18. The stock is trading below the SMA50 of $2.75 and the SMA200 of $2.91, underscoring a technical backdrop of softness in the short run.
| Year | Min | Avg | Max | ROI | Sentiment |
|---|---|---|---|---|---|
| $0.75 | $1.65 | $2.18 | 0% | Neutral | |
| $0.9914 | $1.38 | $2.07 | -17% | Bearish | |
| $0.9498 | $1.40 | $2.24 | -15% | Bearish | |
| $0.7346 | $1.14 | $1.91 | -31% | Bearish | |
| $0.8525 | $1.39 | $2.42 | -16% | Bearish | |
| $1.16 | $1.97 | $3.56 | +20% | Neutral | |
| $1.06 | $1.88 | $3.50 | +14% | Neutral | |
| $0.9928 | $1.83 | $3.50 | +11% | Neutral | |
| $0.9398 | $1.80 | $3.53 | +9% | Neutral | |
| $0.8323 | $1.66 | $3.33 | +1% | Neutral | |
| $1.10 | $2.45 | $5.38 | +48% | Bullish | |
| $1.58 | $3.51 | $8.07 | +113% | Bullish |
Current year — the forecast is anchored to the live price, so ROI shows 0%.
| Month | Min | Avg | Max | Change |
|---|---|---|---|---|
| May 2026 | $0.75 | $1.65 | $1.94 | +0.00% |
| June 2026 | $1.27 | $1.52 | $1.89 | -7.63% |
| July 2026 | $1.26 | $1.54 | $1.96 | +0.95% |
| August 2026 | $1.25 | $1.54 | $2.01 | +0.30% |
| September 2026 | $1.16 | $1.44 | $1.91 | -6.39% |
| October 2026 | $1.14 | $1.44 | $1.92 | -0.49% |
| November 2026 | $1.22 | $1.56 | $2.11 | +8.31% |
| December 2026 | $1.24 | $1.59 | $2.18 | +2.11% |
Click any year to see its month-by-month BIAF forecast. Min / Avg / Max are a bear / base / bull scenario; ROI is the projected move from the current price. Change is the month-over-month move in the average. Estimates, not guarantees.
bioAffinity Technologies, Inc.'s 2026 outlook centres on $1.65, within a $0.75 to $2.18 range. That marks a 0% change versus current levels. A consolidation phase looks the most probable path here.
By 2027, BIAF could reach as high as $2.07, with a base case around $1.38 and support toward $0.9914 — roughly -17% from $1.65. A cyclical pullback looks likely — prices rarely move in a straight line.
Expect BIAF to range from $0.9498 to $2.24 through 2028. The $1.40 average target implies a -15% move from current prices. That is up +2% on the projected 2027 average. Expect choppier, lower action through this leg of the cycle.
The BIAF price prediction for 2029 points to an average of $1.14 (low $0.7346, high $1.91) — a potential decline of -31% on today's $1.65. A cyclical pullback looks likely — prices rarely move in a straight line.
In 2030, BIAF is projected to trade between $0.8525 and $2.42, averaging $1.39 — a potential decline of -16% from today's $1.65. That is up +22% on the projected 2029 average. Expect choppier, lower action through this leg of the cycle.
bioAffinity Technologies, Inc.'s 2031 outlook centres on $1.97, within a $1.16 to $3.56 range. That is up +42% on the projected 2030 average. That marks a +20% change versus current levels. Price action looks broadly range-bound.
By 2032, BIAF could reach as high as $3.50, with a base case around $1.88 and support toward $1.06 — roughly +14% from $1.65. A consolidation phase looks the most probable path here.
Expect BIAF to range from $0.9928 to $3.50 through 2033. The $1.83 average target implies a +11% move from current prices. That is -3% versus the projected 2032 average. Price action looks broadly range-bound.
The BIAF price prediction for 2034 points to an average of $1.80 (low $0.9398, high $3.53) — a potential gain of +9% on today's $1.65. A consolidation phase looks the most probable path here.
In 2035, BIAF is projected to trade between $0.8323 and $3.33, averaging $1.66 — a potential gain of +1% from today's $1.65. That is -8% versus the projected 2034 average. Price action looks broadly range-bound.
bioAffinity Technologies, Inc.'s 2040 outlook centres on $2.45, within a $1.10 to $5.38 range. That is up +47% on the projected 2035 average. That marks a +48% change versus current levels. Buyers look set to stay in control over this stretch.
By 2050, BIAF could reach as high as $8.07, with a base case around $3.51 and support toward $1.58 — roughly +113% from $1.65. Momentum favours further upside here.
Investing $1,000 in BIAF today (≈ 606.060606 BIAF) could be worth
$2,127.23
+$1,127.23 (+113%) by 2050 · US Dollar
Based on the average projected BIAF price of $3.51 in 2050.
Based on the base (average) forecast scenario. FX rates are indicative. Estimates only — not financial advice.
See what a past investment in BIAFwould be worth at today's price.
$1,000 invested in BIAF on May 27, 2025 (≈ 122.549022 BIAF) would be worth
$202.21
-$797.79 (-79.8%) today · 0.20× · US Dollar
Based on a BIAF entry price of $8.16 vs. today's $1.65.
| Invested | Entry price | Value today | Return |
|---|---|---|---|
| 1 week ago | $1.66 | $993.98 | -0.6% |
| 1 month ago | $2.21 | $746.61 | -25.3% |
| 3 months ago | $1.04 | $1,586.54 | +58.7% |
| 6 months ago | $1.5 | $1,100 | +10.0% |
| 1 year ago | $8.16 | $202.21 | -79.8% |
| All time (3.7y) ago | $249 | $6.63 | -99.3% |
Past performance from historical market data — it does not predict future results. FX rates are indicative. Not financial advice.
Enter a price to see how it sits against our BIAF forecast.
Our base-case forecast reaches $3.30 around 2050.
Implied market cap at $3.30: $14.97M
The multi-year forecast shows a cautious start with mixed returns through 2030. The 2026 average is $1.56 with a 0% ROI, and 2027 carries a -16.8% ROI as the sentiment remains Bearish. Through 2030, the average drifts to $1.32 with a -15.3% ROI, reflecting continued downside risk in the near term.
In 2031 the average price rises to $1.89 with a 21% ROI and Bullish sentiment, followed by 2032 at $1.76 (12.6% ROI) and 2033 at $1.74 (11.2% ROI), with neutral sentiment. The 2034–2035 window stays cautious, with 2034 at $1.73 (10.9% ROI) and 2035 at $1.54 (-1.1% ROI).
The horizon brightens toward 2040, where the average is $2.32 with a 48.7% ROI and Bullish sentiment, and further extends to 2050 with an average of $3.31 and a 112.3% ROI, also Bullish. Maximum forecast values reach $5.10 in 2040 and $7.62 in 2050, reflecting significant upside potential amid substantial volatility (annualized volatility around 100%).
Tap a question to reveal the answer.
Avg $1.32, min $0.8116, max $2.30, ROI -15.3%; sentiment BEARISH.
The forecast shows mixed results with negative ROIs in 2027 (-16.8%), 2029 (-31.6%), 2030 (-15.3%), and 2035 (-1.1%), but positive ROIs in 2031 (21%), 2040 (48.7%), and 2050 (112.3%). This indicates high risk and volatility.
Yes. The max forecast price is $5.10 in 2040 and $7.62 in 2050, indicating potential to reach and exceed $5, though these are estimates, not guarantees.
Current price is $1.56 and market cap is $7.07M.
Bearish sentiment with RSI 14 at 30. The 30-day range is $1.04–$2.35. Support is at $1.56 and resistance at $3.18.
bioAffinity Technologies, Inc. Community Discussion
0Share your bioAffinity Technologies, Inc. price prediction and read what the community thinks. Be respectful — comments are public and not financial advice.
Be the first to share your prediction…
What's your take? Add a comment above to start the conversation.